Frost Radar Report: Antibody-Drug Conjugate Contract Development & Manufacturing Organizations

Abzena is recognized as a technology-forward, innovative CDMO in the Frost Radar™: ADC Contract Development and Manufacturing Report, 2025

In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth.

As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan,  shared, “With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its ‘grow-with-the-client’ strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics.”

Download the report to discover what to look for in an ADC CDMO partner and learn more about:

• How Abzena’s proprietary ThioBridge® site-specific conjugation platform improves the design & delivery of ADCs.
• How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs.
• How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors
• How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Download the Report